A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection

K. Kieburtz*, D. Simpson, C. Yiannoutsos, M. B. Max, C. D. Hall, R. J. Ellis, C. M. Marra, R. McKendall, E. Singer, G. J. Dal Pan, D. B. Clifford, T. Tucker, B. Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

232 Scopus citations

Abstract

Background: Painful sensory neuropathy is a common complication of HIV infection. Based on prior uncontrolled observations, we hypothesized that amitriptyline or mexiletine would improve the pain symptoms. Method: A randomized, double-blind, 10-week trial of 145 patients assigned equally to amitriptyline, mexiletine, or matching placebo. The primary outcome measure was the change in pain intensity between baseline and the final visit. Results: The improvement in amitriptyline group (0.31 ± 0.31 units [mean ± SD]) and mexiletine group (0.23 ± 0.41) was not significantly different from placebo (0.20 ± 0.30). Both interventions were generally well tolerated. Conclusions: Neither amitriptyline nor mexiletine provide significant pain relief in patients with HIV-associated painful sensory neuropathy.

Original languageEnglish (US)
Pages (from-to)1682-1688
Number of pages7
JournalNeurology
Volume51
Issue number6
DOIs
StatePublished - Dec 1998

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection'. Together they form a unique fingerprint.

Cite this